STOCK TITAN

Guardant Health closes $550M convertible notes offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) completed a private offering of $550 million aggregate principal amount of 0% convertible senior notes due May 15, 2032, including the initial purchasers’ fully exercised option for an additional $50 million. The senior, unsecured notes bear no regular interest, and the principal does not accrete. Net proceeds were approximately $538.3 million.

Guardant Health used approximately $501.7 million of net proceeds to repurchase approximately $395.2 million aggregate principal amount of its 0% notes due 2027. It used the remaining net proceeds, plus cash on hand, to fund the $51.7 million cost of capped-call transactions, which are expected generally to reduce potential dilution, subject to a cap. The notes’ initial conversion rate is 4.7858 shares per $1,000 principal amount, equivalent to an initial conversion price of approximately $208.95 per share, a 35.0% premium to the November 11, 2026 last reported share price of $154.78. A maximum of 3,553,385 shares may be issued upon conversion based on the initial maximum conversion rate. The capped calls’ initial cap price is $309.56 per share.

Filing Explained

Under the issued notes, holders may convert before February 15, 2032 only when specified conditions apply; afterward they may convert until two trading days before maturity, while Guardant Health chooses whether settlement is in cash, shares, or a mix.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Notes issued $550 million aggregate principal amount 0% Convertible Senior Notes due 2032; completed November 16, 2026
Net proceeds Approximately $538.3 million After initial purchasers’ discounts and commissions and estimated offering expenses
2027 notes repurchased Approximately $395.2 million aggregate principal amount Repurchased for cash using approximately $501.7 million of net proceeds
Capped-call cost $51.7 million Funded with remaining net proceeds plus cash on hand
Initial conversion price Approximately $208.95 per share 35.0% premium to the November 11, 2026 last reported sale price of $154.78 per share
Capped-call cap price $309.56 per share Initial cap price for the capped-call transactions
Maximum shares issuable on conversion 3,553,385 shares Based on the initial maximum conversion rate of 6.4607 shares per $1,000 principal amount
Initial conversion rate 4.7858 shares per $1,000 principal amount Initial rate for the 0% Convertible Senior Notes due 2032
0% Convertible Senior Notes due 2032 financial
"0% Convertible Senior Notes due 2032"
initial conversion rate financial
"The initial conversion rate for the Notes is 4.7858 shares"
The initial conversion rate is the percentage of investors or users who change from one status to another, such as from potential to active, after an initial interaction. It indicates how effectively a process or offering encourages people to take a desired action early on. For investors, a higher initial conversion rate suggests strong interest and a good chance of ongoing engagement or growth.
capped call transactions financial
"privately negotiated capped call transactions"
Capped call transactions are agreements where investors buy options that give them the chance to benefit if a stock's price goes up, but with a limit on how much they can gain. This helps protect them from paying too much if the stock's price rises a lot, similar to having a maximum limit on a reward. They matter because they help investors manage risk while still allowing some upside potential.
provisional redemption financial
"such redemption, a “provisional redemption”"
cleanup redemption financial
"such redemption, a “cleanup redemption”"
A cleanup redemption is a provision that lets an issuer repay the remaining small balance of a loan or bond early once outstanding principal falls below a preset threshold. It matters to investors because it ends future interest payments sooner than expected and forces them to reinvest the returned cash, which can change their expected yield and timing of income—think of it as the issuer sweeping up the last pieces of a puzzle and handing them back to you.
Rule 144A regulatory
"pursuant to the exemption from registration provided by Section 4(a)(2) and Rule 144A"
Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Guardant Health (GH) raise in its 2032 convertible notes offering?

GH completed a private offering of $550 million aggregate principal amount of 0% convertible senior notes due May 15, 2032. The amount includes the initial purchasers’ fully exercised option to purchase an additional $50 million of notes.

How is GH using the proceeds from its convertible notes offering?

GH used approximately $501.7 million of net proceeds to repurchase approximately $395.2 million aggregate principal amount of its 0% notes due 2027. It used the remaining net proceeds, plus cash on hand, to fund the $51.7 million cost of capped-call transactions.

What is the conversion price for GH’s 2032 notes?

The initial conversion price is approximately $208.95 per share, based on an initial conversion rate of 4.7858 shares per $1,000 principal amount. The conversion price represents a 35.0% premium to GH’s last reported sale price of $154.78 per share on November 11, 2026.

When can GH redeem its 2032 convertible notes?

GH may make a provisional redemption on or after November 20, 2029, if its share price meets the indenture’s 130%-of-conversion-price tests. It may also redeem all, but not less than all, of the notes in a cleanup redemption if less than $50.0 million principal amount is outstanding and the notes are freely tradable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001576280 0001576280 2026-11-11 2026-11-11
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 11, 2026

 

 

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38683   45-4139254

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

Indenture and Notes

On November 16, 2026, Guardant Health, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $550 million aggregate principal amount of 0% Convertible Senior Notes due 2032 (the “Notes”), which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $50 million principal amount of Notes.

The Notes were issued pursuant to an indenture, dated November 16, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.

The Notes are senior, unsecured obligations of the Company and will mature on May 15, 2032, unless earlier converted, redeemed, or repurchased. The Notes do not bear regular interest, and the principal amount of the Notes does not accrete. Additional interest and special interest, if any, will accrue on the Notes in the circumstances and at the rates described in the Indenture. Noteholders may convert all or any portion of their Notes only in the following circumstances: (1) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2027, if the last reported sale price (as defined in the Indenture) per share of the Company’s common stock, par value $0.00001 per share (the “common stock”), exceeds 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business day period after any ten consecutive trading day period (the “Measurement Period”) if the trading price (as defined in the Indenture) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate for the Notes on each such trading day; (3) upon the occurrence of certain corporate events or distributions on the common stock as set forth in the Indenture; (4) if the Company calls such Notes for redemption; or (5) at any time from, and including, February 15, 2032 until the close of business on the second scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the common stock or a combination of cash and shares of the common stock, at its election, based on the applicable conversion rate(s).

The initial conversion rate for the Notes is 4.7858 shares of common stock per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $208.95 per share, and is subject to adjustment in accordance with the terms of the Indenture. The initial conversion price of the Notes represents a premium of approximately 35.0% above the last reported sale price of $154.78 per share of the common stock on November 11, 2026. If a “make-whole fundamental change” (as defined in the Indenture) occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time.

The Company may not redeem the Notes at its option at any time before November 20, 2029, except in the event of a cleanup redemption, as described below. The Notes will be redeemable, in whole or in part (subject to the partial redemption limitation described below), at the Company’s option at any time, and from time to time, on a redemption date on or after November 20, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid additional interest and special interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice (such redemption, a “provisional redemption”). Pursuant to the Indenture, the Company may redeem for cash all, but not less than all, of the Notes at any time on or before the 25th scheduled trading day immediately before the maturity date, if (i) the aggregate principal amount of the Notes outstanding at the time the Company sends the related redemption notice is less than $50.0 million; and (ii) the Notes are “freely tradable” (as defined in the Indenture) as of the date the Company sends such notice, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid additional interest and special interest, if any, to, but excluding, the redemption date (such redemption, a “cleanup


redemption”). In addition, calling any Note for a provisional redemption or a cleanup redemption, as applicable, will constitute a make-whole fundamental change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will in certain circumstances be increased in certain circumstances if it is converted after it is called for redemption. In the case of a provisional redemption, pursuant to the partial redemption limitation, the Company may not elect to redeem less than all of the outstanding Notes unless at least $100.0 million aggregate principal amount of Notes are outstanding and not subject to redemption as of the time the Company sends the related redemption notice.

If a “fundamental change” (as defined in the Indenture) occurs, then, except as described in the Indenture, noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid additional interest and special interest, if any, to, but excluding, the fundamental change repurchase date.

The Indenture includes customary covenants and sets forth certain events of default. The following events are considered “events of default” under the Indenture:

 

  •  

default in the payment when due (whether at maturity, upon redemption, upon repurchase upon fundamental change or otherwise) of the principal of, or the redemption price or fundamental change repurchase price for, any Note;

 

  •  

default for 30 consecutive days in the payment when due of additional interest or special interest, if any, that has accrued on any Note;

 

  •  

failure by the Company to deliver, when required by the Indenture, (i) a fundamental change notice or (ii) notice of certain specified corporate events, and, other than in the case of a notice pursuant to (ii), such failure is not cured within three business days after its occurrence;

 

  •  

default in the Company’s obligation to convert a Note in accordance with the Indenture upon the exercise of the conversion right with respect thereto, if such default is not cured within two business days after its occurrence;

 

  •  

failure by the Company to comply with its obligations in respect of any consolidation, merger or sale of assets;

 

  •  

default in any of the Company’s other obligations or agreements under the Indenture or the Notes (other than those specified above) where such default is not cured or waived within 60 days after receipt of written notice of such failure from the trustee or the holders of at least 25% in principal amount of the Notes then outstanding;

 

  •  

default by the Company or any of its significant subsidiaries (as defined in the Indenture) with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed with principal amount in excess of $150.0 million (or its foreign currency equivalent), in the aggregate of the Company and/or any of the Company’s subsidiaries, whether such indebtedness now exists or shall hereafter be created, where such default (i) constitutes a failure to pay the principal of such indebtedness when due and payable at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise, in each case after the expiration of any applicable grace period, or (ii) results in such indebtedness becoming or being declared due and payable before its stated maturity date, in the cases of clauses (i) and (ii), where such default is not cured or waived within 30 days after notice to the Company by the trustee or to the Company and the trustee by holders of at least 25% in aggregate principal amount of the Notes then outstanding in accordance with the Indenture; and

 

  •  

certain events of bankruptcy, insolvency or reorganization of the Company or any of the Company’s significant subsidiaries.

If certain bankruptcy and insolvency-related events of default occur with respect to the Company, the principal of, and accrued and unpaid additional interest and special interest, if any, on, all of the Notes then outstanding shall automatically become due and payable without any further action by any person. If an event of default with respect to the Notes, other than certain bankruptcy and insolvency-related events of default with respect to the Company, occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Notes by notice to the Company and the trustee, may declare 100% of the principal of, and accrued and unpaid additional interest and special interest, if any, on, all the outstanding Notes to be due and payable.

 


Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 360 days after the occurrence of such an event of default, consist exclusively of the right to receive special interest on the Notes.

The Indenture provides that the Company shall not consolidate with or merge with or into, or (directly, or indirectly through one or more of its subsidiaries) sell, lease or otherwise transfer, in one transaction or a series of transactions, all or substantially all of the assets of the Company and its subsidiaries, taken as a whole, to another person, unless: (i) the resulting, surviving or transferee person is the Company or, if not the Company, is a “qualified successor entity” (as defined in the Indenture) duly organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, that expressly assumes by supplemental indenture all of the Company’s obligations under the Indenture and the Notes; and (ii) immediately after giving effect to such transaction, no default or event of default will have occurred and be continuing under the Indenture.

The net proceeds from the Offering, after deducting the initial purchasers’ discounts and commissions and the Company’s estimated offering expenses, were approximately $538.3 million. The Company used approximately $501.7 million of the net proceeds from the Offering to repurchase for cash approximately $395.2 million aggregate principal amount of its existing 0% Convertible Senior Notes due 2027 in privately negotiated transactions entered into concurrently with the pricing of the Offering through one of the initial purchasers or its affiliate, as the Company’s agent. In addition, the Company used the remaining net proceeds, plus cash on hand, to fund the $51.7 million cost of entering into the Capped Call Transactions as described below.

The foregoing description is qualified in its entirety by reference to the text of the Indenture and the form of the Notes, which are attached as Exhibits 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Capped Call Transactions

On November 11, 2026, in connection with the pricing of the Notes, the Company entered into privately negotiated capped call transactions (the “Base Capped Call Transactions”) with certain financial institutions (the “Option Counterparties”), pursuant to capped call confirmations in substantially the form filed as Exhibit 10.1 to this Current Report on Form 8-K and which is incorporated herein by reference. On November 12, 2026, in connection with the initial purchasers’ exercise of their option to purchase additional Notes in full, the Company entered into additional privately negotiated capped call transactions with the Option Counterparties (the “Additional Capped Call Transactions,” and together with the Base Capped Call Transactions, the “Capped Call Transactions”), pursuant to capped call confirmations in substantially the form filed as Exhibit 10.1 to this Current Report on Form 8-K. The Capped Call Transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The Capped Call Transactions are expected generally to reduce potential dilution to the common stock upon any conversion of the Notes or at the Company’s election (subject to certain conditions) offset any cash payments the Company is required to make in excess of the aggregate principal amount of converted Notes, as the case may be, with such reduction or offset subject to a cap. The cap price of the Capped Call Transactions is initially $309.5600, which represents a premium of 100.0% above the last reported sale price of the common stock of $154.78 per share on November 11, 2026, and is subject to certain adjustments under the terms of the Capped Call Transactions.

The Capped Call Transactions are separate transactions entered into by the Company with the Option Counterparties, are not part of the terms of the Notes and will not change the holders’ rights under the Notes. Holders of the Notes will not have any rights with respect to the Capped Call Transactions.

The foregoing description of the Capped Call Transactions contained herein is qualified in its entirety by reference to the text of the form of capped call confirmation relating to the Capped Call Transactions filed as Exhibit 10.1 to this Current Report on Form 8-K and which is incorporated herein by reference.

 


Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 under the heading “Indenture and Notes” of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 3.02

Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 under the heading “Indenture and Notes” of this Current Report on Form 8-K is incorporated herein by reference.

The Company offered and sold the Notes to the initial purchasers in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. The Notes were resold by the initial purchasers to persons reasonably believed to be qualified institutional buyers pursuant to the exemption from registration provided by Section 4(a)(2) and Rule 144A under the Securities Act. The Company relied on these exemptions from registration based in part on representations made by the initial purchasers in the purchase agreement dated November 11, 2026, by and among the Company and the representative of the initial purchasers.

The Notes and the shares of common stock issuable upon conversion of the Notes, if any, have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

To the extent that any shares of common stock are issued upon conversion of the Notes, they will be issued in transactions anticipated to be exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof because no commission or other remuneration is expected to be paid in connection with conversion of the Notes and any resulting issuance of shares of common stock. Initially, a maximum of 3,553,385 shares of common stock may be issued upon conversion of the Notes based on the initial maximum conversion rate of 6.4607 shares of common stock per $1,000 principal amount of Notes, which is subject to customary anti-dilution adjustment provisions.

 

Item 8.01

Other Events.

On November 11, 2026, the Company issued a press release announcing the proposed Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On November 12, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

  

Description

4.1    Indenture, dated November 16, 2026, between Guardant Health, Inc. and U.S. Bank Trust Company, National Association
4.2    Form of 0% Convertible Senior Note due 2032 (included in Exhibit 4.1)
10.1    Form of Capped Call Confirmation
99.1    Press release entitled “Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes due 2032” issued by Guardant Health, Inc. dated November 11, 2026
99.2    Press release entitled “Guardant Health Prices $500.0 Million Convertible Senior Notes Offering” issued by Guardant Health, Inc. dated November 12, 2026
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GUARDANT HEALTH, INC.
Date: November 16, 2026     By:  

/s/ Michael Bell

      Michael Bell
      Chief Financial Officer
      (Principal Financial Officer)

Exhibit 99.1

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032

PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The notes will be senior, unsecured obligations of Guardant Health, will accrue interest payable semi-annually in arrears and will mature on May 15, 2032, unless earlier converted, redeemed or repurchased by Guardant Health. Noteholders will have the right to convert all or any portion of their notes in certain circumstances and during specified periods. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election.

Except as described in the second succeeding sentence with respect to a cleanup redemption, the notes will not be redeemable at Guardant Health’s election at any time before November 20, 2029. The notes will be redeemable, in whole or in part, for cash at Guardant Health’s option at any time, and from time to time, on a redemption date on or after November 20, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Guardant Health’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, Guardant Health may redeem for cash all, but not less than all, of the notes at any time on or before the 25th scheduled trading day immediately before the maturity date if the aggregate principal amount of the notes outstanding at the time Guardant Health sends the related redemption notice is less than $50.0 million and the notes are freely tradable as of the date Guardant Health sends the related redemption notice. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

Guardant Health expects to use a portion of the net proceeds to repurchase for cash a portion of its 0% convertible senior notes due 2027 (the “2027 notes”) in the note repurchase transactions described below. In addition, Guardant Health intends to use a portion of the net proceeds to fund the cost of entering into the capped call transactions described below. Guardant Health intends to use the remainder of the net proceeds, if any, for general corporate purposes. General corporate purposes may include the acquisition of complementary products, technologies, intellectual property or businesses as part of Guardant Health’s growth strategy; however, Guardant Health currently does not have any agreements or commitments to complete any such transactions. If the initial purchasers exercise their option to purchase additional notes, then Guardant Health intends to use a portion of the additional net proceeds from the sale of the additional notes to fund the cost of entering into additional capped call transactions as described below. This press release is not an offer to repurchase any 2027 notes and the offering is not contingent upon the repurchase of any 2027 notes. There can be no assurances that Guardant Health will repurchase any 2027 notes.


In connection with the pricing of the notes, Guardant Health intends to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions (the “option counterparties”). The capped call transactions will cover, subject to customary adjustments, the number of shares of common stock initially underlying the notes. The capped call transactions are expected generally to reduce potential dilution to Guardant Health’s common stock upon conversion of the notes or at Guardant Health’s election (subject to certain conditions) offset any cash payments Guardant Health is required to make in excess of the aggregate principal amount of converted notes, as the case may be, with such reduction or offset subject to a cap.

Guardant Health expects to use a portion of the net proceeds to repurchase for cash a portion of the 2027 notes in privately negotiated transactions (each, a “note repurchase transaction”) entered into concurrently with the pricing of the offering through one of the initial purchasers or its affiliate, as Guardant Health’s agent. The terms of each note repurchase transaction will depend on a variety of factors, including the market price of Guardant Health’s common stock and the trading price of the 2027 notes at the time of such note repurchase transactions. No assurance can be given as to how much, if any, of the 2027 notes will be repurchased or the terms on which they will be repurchased.

Guardant Health has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of Guardant Health’s common stock and/or enter into various derivative transactions with respect to Guardant Health’s common stock concurrently with or shortly after the pricing of the notes. Further, in connection with any note repurchase transaction, Guardant Health expects that holders of the 2027 notes who agree to have their 2027 notes repurchased and who have hedged their equity price risk with respect to such 2027 notes (the “hedged holders”) will, concurrently with, or shortly after, the pricing of the notes or during any agreed measurement period, unwind all or part of their hedge positions by buying Guardant Health’s common stock and/or entering into or unwinding various derivative transactions with respect to Guardant Health’s common stock. The amount of Guardant Health’s common stock that may be purchased by the hedged holders or in connection with such derivative transactions may be substantial in relation to the historic average daily trading volume of Guardant Health’s common stock. These activities by the option counterparties and the hedged holders could increase (or reduce the size of any decrease in) the market price of Guardant Health’s common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. Guardant Health cannot predict the magnitude of any such market activity or the overall effect it would have on the trading price of the notes or Guardant Health’s common stock.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Guardant Health’s common stock and/or purchasing or selling Guardant Health’s common stock or other securities of Guardant Health in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so on each exercise date of


the capped call transactions, which are expected to occur during the 25 trading day period beginning on the 26th scheduled trading day prior to the maturity date of the notes, or following any termination of any portion of the capped call transactions in connection with any repurchase, redemption or early conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Guardant Health’s common stock or the notes, which could affect a noteholder’s ability to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares and value of the consideration that a noteholder will receive upon conversion of the notes.

In addition, if any such capped call transaction fails to become effective, whether or not the offering of the notes is completed, the option counterparty party thereto may unwind its hedge positions with respect to Guardant Health’s common stock, which could adversely affect the value of Guardant Health’s common stock and, if the notes have been issued, the value of the notes.

The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release is not an offer to sell nor a solicitation of an offer to buy any of the securities being offered in the offering or any shares of common stock issuable upon conversion of the notes nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the proposed terms of the notes, the completion, timing and size of the proposed offering, the anticipated terms of, and the effects of entering into, the capped call transactions described above and the actions of the option counterparties or their respective affiliates, the grant to the initial purchasers in the offering of the option to purchase additional notes and the anticipated use of proceeds from the offering, the timing or amount of any potential repurchases of the 2027 notes, and the potential impact of the foregoing or related transactions on


dilution to holders of Guardant Health’s common stock and the market price of Guardant Health’s common stock, the trading price of the notes or the conversion price of the notes, each of which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026 and in its other reports filed with or furnished to the SEC thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Source: Guardant Health, Inc.

Contacts

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Meaghan Smith

press@guardanthealth.com

Exhibit 99.2

Guardant Health Prices $500 Million Convertible Senior Notes Offering

PALO ALTO, Calif. November 12, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on November 16, 2026, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes.

The notes will be senior, unsecured obligations of Guardant Health. The notes will not bear regular interest, and the principal amount of the notes will not accrete. The notes will mature on May 15, 2032, unless earlier converted, redeemed or repurchased by Guardant Health. Before February 15, 2032, noteholders will have the right to convert all or any portion of their notes only in certain circumstances. From and after February 15, 2032 until the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their notes at any time at their election. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. The initial conversion rate is 4.7858 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $208.95 per share of common stock, and will be subject to customary anti-dilution adjustments. The initial conversion price represents a premium of approximately 35.0% above the last reported sale price of $154.78 per share of Guardant Health’s common stock on November 11, 2026.

Except as described in the second succeeding sentence with respect to a cleanup redemption, the notes will not be redeemable at Guardant Health’s election at any time before November 20, 2029. The notes will be redeemable, in whole or in part, for cash at Guardant Health’s option at any time, and from time to time, on a redemption date on or after November 20, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Guardant Health’s common stock exceeds 130% of the conversion price for a specified period of time (each, a “provisional redemption”). In addition, Guardant Health may redeem for cash all, but not less than all, of the notes at any time on or before the 25th scheduled trading day immediately before the maturity date if the aggregate principal amount of the notes outstanding at the time Guardant Health sends the related redemption notice is less than $50.0 million and the notes are freely tradable as of the date Guardant Health sends the related redemption notice (each, a “cleanup redemption”). The redemption price for any provisional redemption or cleanup redemption, as applicable, will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date.


If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to limited exceptions, noteholders may require Guardant Health to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the applicable fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the notes or if Guardant Health delivers a notice of redemption, Guardant Health will, in certain circumstances, increase the conversion rate of the notes for a noteholder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.

Guardant Health estimates that the net proceeds from the offering will be approximately $489.3 million (or approximately $538.3 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. Assuming the initial purchasers exercise their option to purchase additional notes in full and the entry into the additional capped call transactions, Guardant Health expects to use approximately $501.7 million of the net proceeds to repurchase for cash approximately $395.2 million aggregate principal amount of its 0% convertible senior notes due 2027 (the “2027 notes”) in the note repurchase transactions described below and Guardant Health intends to use the remaining net proceeds, plus cash on hand, to fund the $51.7 million cost of entering into the capped call transactions described below. This press release is not an offer to repurchase any 2027 notes and the offering is not contingent upon the repurchase of any 2027 notes.

In connection with the pricing of the notes, Guardant Health entered into privately negotiated capped call transactions with certain financial institutions (the “option counterparties”). The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the notes. The capped call transactions are expected generally to reduce potential dilution to Guardant Health’s common stock upon conversion of the notes or at Guardant Health’s election (subject to certain conditions) offset any cash payments Guardant Health is required to make in excess of the aggregate principal amount of converted notes, as the case may be, with such reduction or offset subject to a cap. The cap price of the capped call transactions is initially $309.5600, which represents a premium of 100.0% above the last reported sale price of Guardant Health’s common stock of $154.78 per share on November 11, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

Assuming the initial purchasers exercise their option to purchase additional notes in full, Guardant Health expects to use approximately $501.7 million of the net proceeds to repurchase for cash approximately $395.2 million aggregate principal amount of the 2027 notes in privately negotiated transactions (each, a “note repurchase transaction”) entered into concurrently with the pricing of the offering through one of the initial purchasers or its affiliate, as Guardant Health’s agent.

Guardant Health has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of Guardant Health’s common stock and/or enter into various derivative transactions with respect to Guardant Health’s common stock concurrently with or shortly after the pricing of the notes. Further, in connection with any note repurchase transaction, Guardant Health expects that holders of the 2027 notes who agreed to have their 2027 notes repurchased and who have hedged their equity price risk with respect to such 2027 notes (the


“hedged holders”) will, concurrently with, or shortly after, the pricing of the notes, unwind all or part of their hedge positions by buying Guardant Health’s common stock and/or entering into or unwinding various derivative transactions with respect to Guardant Health’s common stock. The amount of Guardant Health’s common stock that may be purchased by the hedged holders or in connection with such derivative transactions may be substantial in relation to the historic average daily trading volume of Guardant Health’s common stock. These activities by the option counterparties and the hedged holders could increase (or reduce the size of any decrease in) the market price of Guardant Health’s common stock, including concurrently with the pricing of the notes, which could have resulted in a higher effective conversion price of the notes. Guardant Health cannot predict the magnitude of any such market activity or the overall effect it would have on the trading price of the notes or Guardant Health’s common stock.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Guardant Health’s common stock and/or purchasing or selling Guardant Health’s common stock or other securities of Guardant Health in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so on each exercise date of the capped call transactions, which are expected to occur during the 25 trading day period beginning on the 26th scheduled trading day prior to the maturity date of the notes, or following any termination of any portion of the capped call transactions in connection with any repurchase, redemption or early conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Guardant Health’s common stock or the notes, which could affect a noteholder’s ability to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares and value of the consideration that a noteholder will receive upon conversion of the notes.

In addition, if any such capped call transaction fails to become effective, whether or not the offering of the notes is completed, the option counterparty party thereto may unwind its hedge positions with respect to Guardant Health’s common stock, which could adversely affect the value of Guardant Health’s common stock and, if the notes have been issued, the value of the notes.

The notes sold in the offering were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release is not an offer to sell nor a solicitation of an offer to buy any of the securities being offered in the offering or any shares of common stock issuable upon conversion of the notes, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.


About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the timing and completion of the offering on the anticipated terms, or at all, including statements concerning the expected closing of the offering of the notes, the capped call transactions, any note repurchase transactions, market conditions, statements regarding the expected net proceeds from the offering, the anticipated use of proceeds from the offering, including the note repurchase transactions, and the effects of entering into the capped call transactions described above and the actions of the option counterparties or their respective affiliates, and the potential impact of the foregoing or related transactions on dilution to holders of Guardant Health’s common stock and the market price of Guardant Health’s common stock, the trading price of the notes or the conversion price of the notes, each of which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026 and in its other reports filed with or furnished to the SEC thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.


Source: Guardant Health, Inc.

Contacts

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Meaghan Smith

press@guardanthealth.com

Filing Exhibits & Attachments

7 documents

Keep reading